Chimeric Therapeutics is trading 20% down at A$0.00, with no clear company-specific catalyst identified for the September 25, 2026 move.
- Recent disclosures included an application to quote 22.2 million new shares issued September 22; this may have increased dilution concerns, but available coverage does not directly link it to Friday’s decline.
- Broader biotechnology weakness and risk-off sentiment provide context, though the explanation remains uncertain.